NDB - ≥98% , CAS No.1660153-08-1

CAS: 1660153-08-1 Cat. No.: N650302 분자식: C₂₆H₂₈Cl₂N₂O₂ 분자량: 471.42

등급 & 순도 ≥98%

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

개요

NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research

In Vitro

NDB induces rearrangements of helix 11 (H11) and helix 12 (H12, AF-2) by forming a homodimer of hFXRα-LBD, totally different from the active conformation in monomer state. NDB (25 μM) effectively antagonizes the GW4064-stimulated FXR/RXR interaction and FXRα target gene expression in primary mouse hepatocytes, including the small heterodimer partner (SHP) and bile-salt export pump (BSEP). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

NDB (24 mg/kg; intraperitoneal injection; once a day; for 4 weeks) efficiently decreases the gene expressions of phosphoenolpyruvate carboxykinase (PEPCK), glucose 6-phosphatase (G6-pase), small heterodimer partner, and BSEP in db/db mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL/6J db/db mice (8 weeks of age) Dosage: 24 mg/kg Administration: Intraperitoneal injection; once a day; for 4 weeks Result: Decreased the gene expressions of PEPCK, G6-pase, small heterodimer partner, and BSEP.

Form:Solid

IC50& Target:Human FXRα (hFXRα)

사양

사양 및 순도

≥98%

생화학 및 생리적 메커니즘

NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research.

보관 조건

Store at -20°C

배송

Ice chest + Ice pads

이 제품은 콜드 체인 배송이 필요합니다.지상 및 기타 경제 서비스는 사용할 수 없습니다.

작업 유형

ANTAGONIST

순수함

≥98%

이름과 식별자

분자량

471.42

화학 및 물리적 특성

• 용해성: DMSO : 100 mg/mL (212.13 mM; Need ultrasonic)